Results 201 to 210 of about 18,679,675 (294)

Key outcomes in treatment of activated phosphoinositide 3-kinase delta syndrome: An e-Delphi panel study and responder threshold application. [PDF]

PLoS One
Upton JEM, Williams KW, Cant A, Santos A, Bana E Costa J, Bradt J, Harrington A, Gwaltney C.   +7 more
europepmc   +1 more source

Pleiotropic Roles of FBXO11 in Tumorigenesis: Implications for Targeted Therapy

Cancer Science, EarlyView.
This complex comprises of scaffold CUL1, SKP1, RBX1 and FBXO11 receptor. The substrate is phosphorylated by specific kinase enzyme and recognized by the substrate recognition domain. FBXO11 targets numerous substrates for ubiquitination and degradation, FBXO11 substrates mainly include Snail, ZEB1, p53, BCL6, CDT2, CIITA, Cdc25a, hnRNPA2B1, SAMD1 and ...
Yuqi Zhang, Changyi Fan, Shiheng Chen, Tianyue Lu, Yuanyuan Li, Feng Du, Shanshan Wang   +6 more
wiley   +1 more source

Real-World Health Care Resource Utilization and Costs Among Patients with Activated Phosphoinositide 3-Kinase Delta (PI3Kδ) Syndrome in the United States. [PDF]

Adv Ther
Rider NL, Laliberté F, Germain G, Urosevic A, Mahendran M, Harrington A.   +5 more
europepmc   +1 more source

Daraxonrasib and Beyond: Pan‐RAS Inhibition, Resistance, and Next‐Generation Strategies

Cancer Science, EarlyView.
ABSTRACT RAS proteins have long been considered difficult therapeutic targets, but allele‐selective inhibitors established the clinical tractability of mutant RAS. Daraxonrasib (RMC‐6236), an oral pan‐RAS inhibitor, has now extended this concept by targeting multiple mutant and wild‐type RAS proteins.
Ryo Honda
wiley   +1 more source

Phosphoinositide 3-kinase (PI3K) [PDF]

Science-Business eXchange, 2010
openaire   +3 more sources

Elucidating PI3K/AKT/PTEN Pathway Alterations at Single‐Cell Level in CTCs From HR+/HER2− Metastatic Breast Cancer

Cancer Science, EarlyView.
Single CTC analysis revealed extensive inter‐ and intra‐patient heterogeneity of PI3K/AKT/PTEN pathway alterations in HR+/HER2− metastatic breast cancer, capturing both SNVs and CNAs, including PTEN loss‐of‐function events. Longitudinal CTC profiling also uncovered dynamic clonal evolution, highlighting its potential to complement tissue and ctDNA ...
Tania Rossi, Michela Palleschi, Caterina Gianni, Filippo Merloni, Alessandra Virga, Sara Bandini, Davide Angeli, Michela Tebaldi, Roberta Maltoni, Paola Ulivi, Antonino Musolino   +10 more
wiley   +1 more source

Estimated annual direct medical costs of manifestations among patients with activated phosphoinositide 3-kinase delta syndrome. [PDF]

Clin Exp Med
Hartog NL, Wu EY, Rider NL, Meng Y, Hartline B, Adams P, Aggarwal S, Harrington A.   +7 more
europepmc   +1 more source

Targeting CKIP‐1 for Disease Therapy: Cellular Functions, Molecular Networks, and Clinical Potential

Cell Proliferation, EarlyView.
CKIP‐1, as a scaffold protein with special structural domains, treats related diseases through multiple emerging targeted technologies.
Xin Huang, Shijie Lv, Lejia Li, Jirong Xie, Zhengguo Cao   +4 more
wiley   +1 more source

Functional validation of <i>PIK3R1</i> variant causing activated phosphoinositide 3-kinase-δ syndrome 2 with hypogammaglobulinemia and bronchiectasis. [PDF]

J Hum Immun
Kribis M, Bauman BM, Dutmer CM, Abbott J, Catanzaro J, Lucas CL.   +5 more
europepmc   +1 more source

The insulin‐like growth factor system and the progression of renal complications of type 2 diabetes

Diabetic Medicine, EarlyView.
Abstract Aims Chronic kidney disease is associated with dysregulation of the insulin‐like growth factor (IGF) system. Alterations in IGF bioavailability, driven by IGF binding proteins (IGFBPs), may influence the decline in renal function. However, the longitudinal relationship between baseline IGF‐I, IGF‐II, IGFBPs and progression of kidney ...
Adrian Heald, Yasitha lllangasekera, Andreas Matheou, Ram Prakash Narayanan, Stephen White, Hellena Habte‐Asres, Abigail Lay, Liliana Shalamanova, William Ollier, Graham A. Hitman, Ritwika Mallik, Philip A. Kalra, Martin Whyte, J. Martin Gibson   +13 more
wiley   +1 more source